AC Immune SA (ACIU)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 2.2900 |
| Open | 2.3000 |
| Bid | 2.2900 x 100 |
| Ask | 2.4100 x 100 |
| Day's range | 2.2500 - 2.4952 |
| 52-week range | 1.7800 - 5.1400 |
| Volume | |
| Avg. volume | 184,015 |
| Market cap | 232.412M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings date | 26 Apr 2024 - 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.51 |
Simply Wall St.We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Simply Wall St.
Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%
AC Immune SA ( NASDAQ:ACIU ) shareholders should be happy to see the share price up 17% in the last month. But over the...
Globe NewswireAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designationACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partnerCash of CHF 103 million at year end, plus the CHF 15 million
© 2024 Yahoo. All rights reserved.